Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of research analysts have recently commented on COLL shares. Needham & Company LLC cut their price objective on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday. Barclays lowered their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the transaction, the executive vice president directly owned 71,770 shares of the company’s stock, valued at approximately $2,900,225.70. This trade represents a 41.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the company. Group One Trading LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd lifted its holdings in Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the last quarter. Federated Hermes Inc. boosted its position in Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter worth about $61,000. Finally, CWM LLC grew its stake in Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 1,153 shares during the last quarter.

Collegium Pharmaceutical Trading Up 0.0%

Shares of COLL stock opened at $37.29 on Monday. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $50.79. The firm’s fifty day simple moving average is $45.48 and its 200 day simple moving average is $42.08. The firm has a market capitalization of $1.18 billion, a P/E ratio of 21.81 and a beta of 0.67. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). The company had revenue of $205.45 million for the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. Collegium Pharmaceutical’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.77 earnings per share. As a group, sell-side analysts predict that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.